BPG is committed to discovery and dissemination of knowledge
Articles in Press
7/4/2020 4:10:00 AM | Browse: 293 | Download: 407
Publication Name World Journal of Gastroenterology
Manuscript ID 55265
Country China
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
Manuscript Source Unsolicited Manuscript
All Author List Dong-Xu Wang, Xu Yang, Jian-Zhen Lin, Yi Bai, Jun-Yu Long, Xiao-Bo Yang, Samuel Seery and Hai-Tao Zhao
Funding Agency and Grant Number
Funding Agency Grant Number
International Science and Technology Cooperation Projects 2016YFE0107100
Capital Special Research Project for Health Development 2014-2-4012
Beijing Natural Science Foundation L172055
Beijing Natural Science Foundation 7192158
National Ten-thousand Talent Program, the Fundamental Research Funds for the Central Universities 3332018032
CAMS Innovation Fund for Medical Science (CIFMS) 2017-I2M-4-003
CAMS Innovation Fund for Medical Science (CIFMS) 2018-I2M-3-001
Corresponding Author Hai-Tao Zhao, MD, Professor, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1, Shuaifuyuan, Wangfujing, Beijing 100730, China. zhaoht@pumch.cn
Key Words Lenvatinib; Real-world study; Hepatocellular carcinoma; Efficacy; Safety; Treatment
Core Tip This is a real-world study for advanced hepatocellular carcinoma patients treated with lenvatinib monotherapy in China. The majority of patients in this study presented with hepatitis B virus infection. Our analysis of the safety and efficacy of this intervention confirms previous evidence from the phase III REFLECT study. Multivariate analysis of participant characteristics with changes in serum biomarkers and gene sequencing provides a more comprehensive understanding of lenvatinib responses. This new knowledge, even though based on a small sample, has clinical implications and necessitates further research.
Citation Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478
Received
2020-03-14 16:20
Peer-Review Started
2020-03-14 16:21
To Make the First Decision
Return for Revision
2020-04-12 02:13
Revised
2020-04-25 10:59
Second Decision
2020-07-02 10:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-07-04 04:10
Articles in Press
2020-07-04 04:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
2020-07-16 06:02
Typeset the Manuscript
2020-08-14 01:17
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com